Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 6672

1.

Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.

Wang J, Liu Z, Cui Y, Liu Y, Fang J, Xu L, He Y, Du J, Su Y, Zou W, Xu Z, Li G.

J Neurooncol. 2019 Jun 18. doi: 10.1007/s11060-019-03212-0. [Epub ahead of print]

PMID:
31214915
2.

Disparities among racial/ethnic groups of patients diagnosed with ependymoma: analyses from the Surveillance, Epidemiology and End Results (SEER) registry.

Stenzel AE, Fenstermaker RA, Wiltsie LM, Moysich KB.

J Neurooncol. 2019 Jun 17. doi: 10.1007/s11060-019-03214-y. [Epub ahead of print]

PMID:
31209774
3.

Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.

Truitt G, Gittleman H, Leece R, Ostrom QT, Kruchko C, Armstrong TS, Gilbert MR, Barnholtz-Sloan JS.

J Neurooncol. 2019 Jun 17. doi: 10.1007/s11060-019-03215-x. [Epub ahead of print]

PMID:
31209773
4.

Growth rate and fate of untreated hemangioblastomas: clinical assessment of the experience of a single institution.

Byun J, Yoo HJ, Kim JH, Kim YH, Cho YH, Hong SH, Kim CJ.

J Neurooncol. 2019 Jun 14. doi: 10.1007/s11060-019-03213-z. [Epub ahead of print]

PMID:
31201685
5.

Temporary blood-brain barrier disruption by low intensity pulsed ultrasound increases carboplatin delivery and efficacy in preclinical models of glioblastoma.

Dréan A, Lemaire N, Bouchoux G, Goldwirt L, Canney M, Goli L, Bouzidi A, Schmitt C, Guehennec J, Verreault M, Sanson M, Delattre JY, Mokhtari K, Sottilini F, Carpentier A, Idbaih A.

J Neurooncol. 2019 Jun 13. doi: 10.1007/s11060-019-03204-0. [Epub ahead of print]

PMID:
31197598
6.

Prognostic markers for immunodeficiency-associated primary central nervous system lymphoma.

Kaulen LD, Galluzzo D, Hui P, Barbiero F, Karschnia P, Huttner A, Fulbright R, Baehring JM.

J Neurooncol. 2019 Jun 13. doi: 10.1007/s11060-019-03208-w. [Epub ahead of print]

PMID:
31190317
7.

A novel finding of an IDH2 mutation in an interesting adult Sonic Hedgehog mutated medulloblastoma.

Fomchenko EI, Erson-Omay EZ, Moliterno J.

J Neurooncol. 2019 Jun 12. doi: 10.1007/s11060-019-03207-x. [Epub ahead of print] No abstract available.

PMID:
31187320
8.

Quality-adjusted life years in glioma patients: a systematic review on currently available data and the lack of evidence-based utilities.

Butenschoen VM, Kelm A, Meyer B, Krieg SM.

J Neurooncol. 2019 Jun 12. doi: 10.1007/s11060-019-03210-2. [Epub ahead of print] Review.

PMID:
31187319
9.

Smoking status and perioperative adverse events in patients undergoing cranial tumor surgery.

Padevit L, Sarnthein J, Stienen MN, Krayenbühl N, Bozinov O, Regli L, Neidert MC.

J Neurooncol. 2019 Jun 11. doi: 10.1007/s11060-019-03206-y. [Epub ahead of print]

PMID:
31183602
10.

Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.

Hao S, Huang G, Feng J, Li D, Wang K, Wang L, Wu Z, Wan H, Zhang L, Zhang J.

J Neurooncol. 2019 Jun 8. doi: 10.1007/s11060-019-03198-9. [Epub ahead of print]

PMID:
31177425
11.

Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.

Jiang H, Zeng W, Ren X, Cui Y, Li M, Yang K, Elbaroody M, Lin S.

J Neurooncol. 2019 Jun 7. doi: 10.1007/s11060-019-03211-1. [Epub ahead of print]

PMID:
31175579
12.

LncRNA GAS5 regulates the proliferation, migration, invasion and apoptosis of brain glioma cells through targeting GSTM3 expression. The effect of LncRNA GAS5 on glioma cells.

Li G, Cai Y, Wang C, Huang M, Chen J.

J Neurooncol. 2019 Jun 6. doi: 10.1007/s11060-019-03185-0. [Epub ahead of print]

PMID:
31172354
13.

Radiotherapy for recurrent intracranial epidermoid cysts without malignant transformation: a single-institution case series.

Morshed RA, Wu SY, Sneed PK, McDermott MW.

J Neurooncol. 2019 Jun 5. doi: 10.1007/s11060-019-03202-2. [Epub ahead of print]

PMID:
31168670
14.

Correction to: Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG).

Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E.

J Neurooncol. 2019 Jun 5. doi: 10.1007/s11060-019-03201-3. [Epub ahead of print]

PMID:
31165953
15.

Triptolide reverses helper T cell inhibition and down-regulates IFN-γ induced PD-L1 expression in glioma cell lines.

Zhang L, Yu JS.

J Neurooncol. 2019 May 31. doi: 10.1007/s11060-019-03193-0. [Epub ahead of print]

PMID:
31152305
16.

CD146 is highly expressed in glioma stem cells and acts as a cell cycle regulator.

Yawata T, Higashi Y, Kawanishi Y, Nakajo T, Fukui N, Fukuda H, Ueba T.

J Neurooncol. 2019 May 30. doi: 10.1007/s11060-019-03200-4. [Epub ahead of print]

PMID:
31147892
17.

Applicability and limitations of a recently-proposed prognostic grading metric, initial brain metastasis velocity, for brain metastasis patients undergoing stereotactic radiosurgery.

Yamamoto M, Aiyama H, Koiso T, Watanabe S, Kawabe T, Sato Y, Higuchi Y, Kasuya H, Barfod BE.

J Neurooncol. 2019 May 28. doi: 10.1007/s11060-019-03199-8. [Epub ahead of print]

PMID:
31140039
18.

The case for radiosurgery for brainstem metastases.

Winograd E, Rivers CI, Fenstermaker R, Fabiano A, Plunkett R, Prasad D.

J Neurooncol. 2019 May 24. doi: 10.1007/s11060-019-03195-y. [Epub ahead of print]

PMID:
31127508
19.

Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model.

Connock M, Auguste P, Dussart C, Guyotat J, Armoiry X.

J Neurooncol. 2019 May 24. doi: 10.1007/s11060-019-03197-w. [Epub ahead of print]

PMID:
31127507
20.

Multisession radiosurgery for perioptic meningiomas: medium-to-long term results from a CyberKnife cooperative study.

Marchetti M, Conti A, Beltramo G, Pinzi V, Pontoriero A, Tramacere I, Senger C, Pergolizzi S, Fariselli L.

J Neurooncol. 2019 May 22. doi: 10.1007/s11060-019-03196-x. [Epub ahead of print]

PMID:
31119480

Supplemental Content

Loading ...
Support Center